Kiniksa Pharmaceuticals International Plc (KNSA) Stock Price, Quote & News

Company Profile

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chron...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 431 9100

Website: www.kiniksa.com

Address:

23 Old Bond Street, Floor 3, London, United Kingdom

limitsean Oct. 5 at 9:19 AM

$KNSA Biotech with clinical catalyst. High short interest. Volatility expansion expected. Pure binary event risk.

0 · Reply

highnihilism Oct. 1 at 7:34 AM

0 · Reply

BDE_Worldwide Sep. 29 at 9:47 PM

$KNSA very quiet board for hitting all time highs.. 🤔 Takeout candidate in 2026.

1 · Reply

Rascal7777777 Sep. 29 at 7:23 PM

$VRNA $KNSA ????

1 · Reply

ap20 Sep. 29 at 6:20 PM

$KNSA Cowen upgrade to 60. 52 week and I think all time high today on decent volume.

0 · Reply

xbibackto65s Sep. 25 at 8:26 PM

$KNSA fn dick tease all day w flat and slight green!

0 · Reply

xbibackto65s Sep. 19 at 3:19 PM

$KNSA addind more

0 · Reply

xbibackto65s Sep. 18 at 7:09 PM

$KNSA wake up!!! look at xbi!!

0 · Reply

xbibackto65s Sep. 15 at 3:21 PM

$KNSA Adding

0 · Reply

ap20 Sep. 8 at 4:54 PM

$KNSA Nice little run continues.

0 · Reply

Kiniksa Pharmaceuticals International, Plc (KNSA) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 28, 2025, 4:01 PM EDT - 5 weeks ago

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Jul 29, 2025, 10:34 AM EDT - 2 months ago

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:30 AM EDT - 2 months ago

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

Jul 24, 2025, 4:01 PM EDT - 2 months ago

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

Jun 16, 2025, 8:15 AM EDT - 3 months ago

Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast

Jun 5, 2025, 7:00 AM EDT - 4 months ago

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

May 5, 2025, 4:51 PM EDT - 5 months ago

Kiniksa Pharmaceuticals: Making Steady Progress

Apr 30, 2025, 8:30 AM EDT - 5 months ago

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Apr 29, 2025, 3:07 PM EDT - 5 months ago

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 7:30 AM EDT - 5 months ago

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Apr 24, 2025, 4:01 PM EDT - 5 months ago

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

Feb 25, 2025, 4:14 PM EST - 7 months ago

Big Pipeline Updates From Kiniksa Pharmaceuticals

Feb 25, 2025, 10:53 AM EST - 7 months ago

Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:30 AM EST - 7 months ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Feb 25, 2025, 7:29 AM EST - 7 months ago

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Feb 20, 2025, 4:01 PM EST - 8 months ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Jan 13, 2025, 7:30 AM EST - 9 months ago

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Jan 6, 2025, 4:01 PM EST - 9 months ago

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 4:01 PM EST - 11 months ago

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 4:01 PM EST - 11 months ago

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Oct 29, 2024, 11:45 AM EDT - 1 year ago

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Jul 24, 2024, 5:38 AM EDT - 1 year ago

Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat

Jul 23, 2024, 1:30 PM EDT - 1 year ago

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call Transcript

Jul 23, 2024, 7:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative

Jun 4, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 7, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

Apr 24, 2024, 1:34 PM EDT - 1 year ago

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

Apr 23, 2024, 1:59 PM EDT - 1 year ago

Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript

Apr 23, 2024, 7:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

Apr 16, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

Apr 2, 2024, 7:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Feb 28, 2024, 11:58 AM EST - 1 year ago

Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 7:30 AM EST - 1 year ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

Feb 21, 2024, 4:01 PM EST - 1 year ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Jan 5, 2024, 4:29 PM EST - 1 year ago

Kiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed Bag

Jan 4, 2024, 7:30 AM EST - 1 year ago

Kiniksa Pharmaceuticals Provides Corporate Update

Jan 2, 2024, 4:01 PM EST - 1 year ago

Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nov 3, 2023, 11:07 AM EDT - 2 years ago

Kiniksa Pharmaceuticals: Arcalyst Performs While KPL-404 Advances Toward Early 2024 Readout

Oct 31, 2023, 2:35 PM EDT - 2 years ago

Kiniksa Pharmaceuticals Ltd (KNSA) Q3 2023 Earnings Call Transcript

Oct 31, 2023, 7:30 AM EDT - 2 years ago

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

Oct 24, 2023, 4:01 PM EDT - 2 years ago

Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023

Jul 27, 2023, 10:57 AM EDT - 2 years ago

Kiniksa Pharmaceuticals: Arcalyst's Growth Picks Up

Jul 25, 2023, 12:22 PM EDT - 2 years ago

Kiniksa Pharmaceuticals Ltd (KNSA) Q2 2023 Earnings Call Transcript

limitsean Oct. 5 at 9:19 AM

$KNSA Biotech with clinical catalyst. High short interest. Volatility expansion expected. Pure binary event risk.

0 · Reply

highnihilism Oct. 1 at 7:34 AM

0 · Reply

BDE_Worldwide Sep. 29 at 9:47 PM

$KNSA very quiet board for hitting all time highs.. 🤔 Takeout candidate in 2026.

1 · Reply

Rascal7777777 Sep. 29 at 7:23 PM

$VRNA $KNSA ????

1 · Reply

ap20 Sep. 29 at 6:20 PM

$KNSA Cowen upgrade to 60. 52 week and I think all time high today on decent volume.

0 · Reply

xbibackto65s Sep. 25 at 8:26 PM

$KNSA fn dick tease all day w flat and slight green!

0 · Reply

xbibackto65s Sep. 19 at 3:19 PM

$KNSA addind more

0 · Reply

xbibackto65s Sep. 18 at 7:09 PM

$KNSA wake up!!! look at xbi!!

0 · Reply

xbibackto65s Sep. 15 at 3:21 PM

$KNSA Adding

0 · Reply

ap20 Sep. 8 at 4:54 PM

$KNSA Nice little run continues.

0 · Reply

Massimino Sep. 8 at 12:49 PM

$KNSA my best performing stock this year!!

0 · Reply

Doozio Sep. 5 at 12:52 PM

$KNSA out of the tightness during 🐒🍌🧠⏰♾️

0 · Reply

Happy_Feet19 Sep. 3 at 10:02 PM

$KNSA Good fireside chat today. They have a very detailed updated corp. presentation on their website. I have ask this question in the past years that I have owned this stock but can anyone tell me why this great company with awesome revenue with no competition is not for sale. I would think some big parma like Roche would buy them out. Thoughts?

1 · Reply

ap20 Sep. 3 at 7:12 PM

$KNSA nice move today.

0 · Reply

ap20 Aug. 31 at 1:41 AM

$KNSA 26 days without a post.. I thought I’d post something.. It hasn’t gone down!

0 · Reply

topstockalerts Aug. 4 at 10:56 AM

Pre Market Top Gainers PT2 $UNIT $SLE $BTAI $KNSA $BLDE

0 · Reply

WallStreetBuyDip Aug. 3 at 2:59 AM

$KNSA Trading at $31.98, hitting the highest point today. With an average volume of 551,318, today's volume is lower than yesterday's.

0 · Reply

BDE_Worldwide Aug. 1 at 8:35 PM

$KNSA really digging this move today! Finally time to put $30 in the rearview??

0 · Reply

OptionRunners Aug. 1 at 7:16 PM

$KNSA taking out the earnings highs from a few days ago. Really strong today in this ugly tape. Calls up to about $3.70 now Guy in the comments was arguing with me about how they were selling them lol. Careful who you follow.

0 · Reply

BioTechHealthX Jul. 31 at 2:18 PM

$KNSA With record earnings, a growing pipeline, and analysts upgrading targets, Kiniksa may be on the verge of a massive rally in 2025. https://biotechhealthx.com/biotech-news/kiniksa-pharmaceuticals-knsa-is-breaking-out/

0 · Reply

TaxiBiotech_ Jul. 30 at 2:08 PM

$KNSA Kiniksa $KNSA 🇺🇸 • Q2 revenue: $156.8M (+52%) • Q2 OpEx: $136.6M • Cash: $307.8M • 3,475 active prescribers 🔬 Phase 2/3 trial for KPL‑387 (pericarditis) underway 🗓️ Data expected in 2026 https://investors.kiniksa.com/news-events/press-releases/

0 · Reply

d_risk Jul. 30 at 11:56 AM

$KNSA - Kiniksa Pharmaceuticals International plc Class A Ordinary Shares - 10Q - Updated Risk Factors Kiniksa’s 2025 10-Q highlights heightened risks from reliance on specialty pharmacies, complex global pricing and regulatory hurdles, clinical trial uncertainties, supply chain and manufacturing transitions, intensified competition, expanded IP litigation exposure, evolving healthcare laws, cybersecurity threats, ESG and climate impacts, key personnel retention challenges, and shareholder concentration risks—all potentially impacting financial and operational outcomes. #SpecialtyPharmacies #ShareholderConcentration #KeyPersonnelRetention #ESGImpact #CybersecurityThreats #HealthcareLaws #IPLitigation #SupplyChainTransition #ClinicalTrialRisks #RegulatoryChallenges 🟢 Added 🟠 Removed https://d-risk.ai/KNSA/10-Q/2025-07-29

0 · Reply

Market Cap	2.85B
Revenue (ttm)	423.24M
Net Income (ttm)	-43.19M
EPS (ttm)	N/A
PE Ratio	936.75
Forward PE	38.04
Profit Margin	-10.20%
Debt to Equity Ratio	0.00

Volume	608,900
Avg Vol	538,500
Day's Range	N/A - N/A
Shares Out	74.11M
Stochastic %K	83%
Beta	0.16
Analysts	Strong Sell
Price Target	$47.12